Recent Advances in Nanomedicine-Based Cancer Immunotherapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 2002
Special Issue Editors
Interests: T-cell immunology; non-Hodgkin lymphoma; immunotherapy; nanomedicine
Interests: endocrine cancers; aberrant glycans
Special Issues, Collections and Topics in MDPI journals
Interests: stem cells; premalignancy; disease modeling; drug discovery; nanotechnology; lung cancer; immuno-oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
It is our pleasure to announce a call for submissions to this Special Issue of Cancers, "Recent Advances in Nanomedicine-Based Cancer Immunotherapy". Cancer is a leading cause of death worldwide. Nearly 10 million deaths related to cancer were recorded in 2020 by the World Health Organization. With substantial innovation in early diagnosis and effective treatment regimens, many cancers have a high chance of cure. Exciting advances over the past decade have led to immunotherapies that harness the powerful antitumor activity of the immune system to fight cancer. Immunotherapies have proven a miracle for several types of cancers, including melanoma, lymphoma, bladder cancer, stomach cancer, liver cancer, kidney cancer, head and neck cancers, breast cancer, small cell lung cancer, and non-small cell lung cancer. However, challenges remain. They do not work for all patients and are associated with long-term adverse effects, toxicities, drug resistance, and autoimmunity. In this context, recent advancements in nanotechnologies have greatly improved the effectiveness of cancer immunotherapies.
This Special Issue aims to provide a comprehensive overview of the principles, techniques, new advancements, and recent discoveries, from basic research to clinical translation, of applying nanotechnologies in the field of cancer immunotherapies.
In this Special Issue, original research articles, reviews, and commentaries that cover the relevant topics in this area are welcome. We also solicit work on completed and/or ongoing clinical trials utilizing nanotechnologies for enhancing the effectiveness of cancer therapeutics. Findings from studies employing advanced molecular nanotechnologies in nano-enabled therapeutics are also welcome. Topics include, but are not limited to, the following:
- Combination immune checkpoint inhibitors with core–shell nanoparticles;
- Functionalized or biomimetic nanoparticle design and engineering for immunotherapy;
- Nanomedicine for immune-stimulatory molecules;
- CRISPR-Cas nanoparticles in immunotherapy;
- Nanotechnology delivery platform for immunotherapies or CAR T-cells;
- Nanomedicine bispecific antibodies;
- Nanomedicine oncolytic virotherapies;
- Nanotechnologies overcoming resistance, side effects, or toxicities of immunotherapies;
- Nanotechnologies for identifying new biomarkers of immunotherapies;
- Pharmacokinetics of nanomedicine-based cancer immunotherapy.
We look forward to receiving your contributions.
Dr. Navin Kumar Verma
Dr. Rajeev Parameswaran
Dr. Manash Paul
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer nano-therapy
- nano-enabled therapeutic
- immune checkpoint inhibitors
- tumor immunosuppression
- adoptive cell therapy
- CAR T-cell therapy
- tumor-infiltrating lymphocyte therapy
- monoclonal antibody therapy for cancer
- cancer vaccines
- immune system modulators
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
